Patients who use GLP1 drugs to help control their type 2 diabetes are at an upward risk of developing age-related macular ...

Body image is part physical and part mental. If weight loss alone isn't helping, strategies from body image psychology can ...

Weight-loss drugs are already dropping in price; could they go even lower? - Consumers are now able to pay roughly $500 for ...

These five Dow Jones industrial companies have paid dividends for at least 100 years, perfect ideas for long-term growth and ...

GLP-1s are gaining interest for their impact on weight, blood sugar, and possibly mood in bipolar disorder. Here’s what ...

The Indianapolis-based drugmaker sees orforglipron as a potential global breakthrough treatment for weight loss and other ...

Later this month, the Street will have a fresh opportunity to gauge the potential for Amgen's experimental weight-loss drug, MariTide.

Omada Health shares climbed after the company made its debut on Nasdaq. The virtual healthcare company started trading shares at $19 on Friday morning, and they jumped 35% to $25.58 by midday. It ...

A new study brings into focus the relationship between diabetic GLP-1 users and the elevated risk of age-related eye disease.

In the past, studies in type-2 diabetes patients have linked Ozempic to the condition called non-arteritic anterior ischemic ...

Weight-loss drugs like Ozempic and Wegovy are used by more than 15 million adults in the U.S., or 4.5% of the population.